Show simple item record

dc.contributor.authorKremer, Lisa
dc.contributor.authorMedlicott, Natalie
dc.contributor.authorReith, David
dc.contributor.authorBroadbent, Roland
dc.date.available2017-10-26T20:50:47Z
dc.date.copyright2017
dc.identifier.citationKremer, L., Medlicott, N., Reith, D., & Broadbent, R. (2017). Lack of evidence and consequential harm caused by mydriatic regimens used in retinopathy of prematurity screening. Presented at the Otago Spotlight Series: Child Health Research 2017.en
dc.identifier.urihttp://hdl.handle.net/10523/7637
dc.description.abstractApproximately 3,500 infants in New Zealand and Australia are screened annually for retinopathy of prematurity (ROP). To view the retina and diagnose ROP, adequate pupil dilation with mydriatic medicines is required. Although mydriatic drops are in common use in NICUs, there is no established or preferred mydriatic regimen in New Zealand and Australia. A literature review revealed that there is very limited literature involving only pilot studies on which international mydriatic guidelines are based. Results from these pilot studies suggest that there is very little benefit in administering larger doses when smaller doses are effective. A survey of New Zealand and Australian neonatal nursing staff identified 11 different mydriatic regimens, highlighting the need for robust evidence to guide clinical practice. Within these 11 mydriatic regimens, there was up to a 27-fold difference in total dose. Only 22% of the respondents indicated using a microdrop to reduce the total dose. The larger the total dose of mydriatic medicines, the higher the risk for adverse events. Adverse events that neonatal nurses reported after mydriatic administration were; hypertension, tachycardia, apnoea, feed intolerance, abdominal distension, necrotising enterocolitis, death and periorbital pallor. The findings indicate the need for further evidence to support the dosing of mydriatics in neonates. There is a need for a RCT to investigate the use of low dose cyclopentolate and phenylephrine by comparing a standard drop to a microdrop. Results from the RCT will provide evidence for international guidelines, and therefore guide clinical practice.en_NZ
dc.format.mimetypeapplication/pdf
dc.language.isoenen_NZ
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleLack of evidence and consequential harm caused by mydriatic regimens used in retinopathy of prematurity screening.en_NZ
dc.typeConference or Workshop Item (Poster)en_NZ
dc.date.updated2017-10-20T20:08:58Z
otago.schoolSchool of Pharmacy, University of Otago.en_NZ
otago.schoolDepartment of Women’s and Children’s Health, University of Otago.en_NZ
otago.openaccessOpenen_NZ
otago.event.placeWellingtonen_NZ
otago.event.titleOtago Spotlight Series: Child Health Research 2017en_NZ
 Find in your library

Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International